ArticleMetabolic brain disease2026
Lipocalin-2 deficiency attenuates kainic acid-induced hippocampal cell death in a high-fat diet-fed diabetic mice.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunctions such as obesity and diabetes predispose the brain to heightened excitotoxic vulnerability, aggravating neuronal injury and cognitive decline. This study investigated the mechanistic role of lipocalin-2 (LCN2) in metabolic stress-amplified hippocampal damage following kainic acid (KA) exposure. Using high-fat diet (HFD)-fed diabetic wild type (WT) and LCN2 knockout (LCN2KO) mice, we found that LCN2 deficiency improved systemic insulin sensitivity and alleviated hepatic steatosis. In the diabetic hippocampus, LCN2 deletion markedly reduced KA-induced neuronal apoptosis, blood-brain barrier leakage, and iron-mediated oxidative stress. LCN2 ablation suppressed activation of microglia and astrocytes, downregulated galectin-3 and pro-inflammatory cytokines, and inhibited signal transducer and activator of transcription 3 (STAT3)-NF-κBp65-dependent signaling in KA-treated diabetic hippocampus. Reduced autophagy-related protein expression and protein aggregation in KA-treated diabetic LCN2KO mice indicated that LCN2 amplifies excitotoxic stress through autophagic and inflammatory mechanisms. These results identify LCN2 as a pivotal mediator linking metabolic dysfunction to neuroinflammation, ferroptosis, microglial activation, and autophagy in the diabetic hippocampus with excitotoxicity, suggesting that targeting the microglial LCN2-STAT3-NF-κBp65 axis may offer therapeutic potential for metabolic disease-associated acute brain injury.
Indexed as
Identifiers
41661361What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.